Prescription medication · Guanylate Cyclase-C Agonist

plecanatide

Also sold as Trulance. Trulance treats chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

Data updated 2026-05-15

1,831
FDA reportsRarely reported
$17.84
Brand price (NADAC)

plecanatide (Trulance) is a prescription Guanylate Cyclase-C Agonist. Trulance treats chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

Trulance is a medicine that helps adults with certain bowel problems. It helps your bowels move more regularly.

Drug Pricing (NADAC)

Brand Price

$17.84/unit

Generic Available

No

SALIX

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

View Alternatives → Compare with Another Drug → Full Side Effects Report →

What it does

Trulance treats chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

Common side effects

Diarrhea

Key warnings

Trulance can cause serious dehydration in children under 6.

The sections below are summarized in plain English from plecanatide's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Trulance is a guanylate cyclase-C agonist. It works by increasing fluid in your intestines. This helps to soften stool and make bowel movements easier.

Side Effects (from patient reports)

Based on 1,831 FDA adverse event reports.

Most-reported reactions

Adverse reactions in FAERS for plecanatide, by number of reports

reports

What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.

Source FDA Adverse Event Reporting System (FAERS) As of 2025

Reports over time

Adverse-event reports filed for plecanatide each year to the FDA Adverse Event Reporting System (FAERS).

0100200300 2016201720182019202020212022202320242025 182

Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.

Where plecanatide sits

plecanatide has more FDA adverse-event reports than 11% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.

fewest reports most reports

Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is plecanatide; the line is the median (50th percentile).

FDA Adverse Event Report Analysis

Detailed analysis of 1,831 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2016–2025.

Total Reports

1,831

Reports Mentioning Death

72

3.9% of reports — not proof of cause

Hospitalization Reports

254

Top Indication

Product Used For Unknown Indication

Gender Distribution

Female 1,154 (79%)
Male 302 (21%)

Age Distribution

0–17 9
18–44 176
45–64 347
65–74 217
75+ 157

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
1 DIARRHOEA 363
2 NAUSEA 159
4 CONSTIPATION 152
5 FATIGUE 106
6 ABDOMINAL DISTENSION 100
7 ABDOMINAL PAIN UPPER 100
8 ABDOMINAL PAIN 96
9 HEADACHE 96
10 PAIN 95
11 DIZZINESS 87
13 DYSPNOEA 68
14 MUSCLE SPASMS 68
15 MALAISE 67
16 ABDOMINAL DISCOMFORT 66
17 FLATULENCE 64

Reactions in Death Reports

DEATH 60
CONSTIPATION 5
ASTHENIA 3
FALL 3
HALLUCINATION 3
TREMOR 3
ABDOMINAL DISTENSION 2
ANKLE FRACTURE 2
CARDIAC ARREST 2
CARDIAC DISORDER 2

Reactions in Hospitalization Reports

NAUSEA 33
FALL 31
DIARRHOEA 30
CONSTIPATION 25
FATIGUE 24
HEADACHE 24
HOSPITALISATION 24
DIZZINESS 21
PAIN 21
COVID-19 20

Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Trulance can cause serious dehydration in children under 6. You should not give Trulance to children under 6 years old. Avoid using Trulance in patients 6 years to less than 18 years of age.

Common Questions

What is the dose of Trulance?
The dose is 3 mg taken by mouth once a day.
Can I take Trulance with food?
Yes, you can take Trulance with or without food.
What should I do if I get severe diarrhea?
Stop taking Trulance and drink plenty of fluids to rehydrate.
Can I give Trulance to my child?
No, you should not give Trulance to children under 6 years old. Avoid using Trulance in patients 6 years to less than 18 years of age.
How should I store Trulance?
Store Trulance at room temperature in a dry place.
What if I have trouble swallowing the tablet?
You can crush the tablet and mix it with applesauce or water.
Can I mix Trulance with other foods or liquids?
No, only mix crushed Trulance tablets with applesauce or water.
What if part of the crushed tablet is left in the cup?
Add more water, swirl, and swallow immediately.
Is Trulance safe to take during pregnancy?
It is not expected that Trulance will harm your unborn baby.
Can I take Trulance while breastfeeding?
Yes, Trulance is not expected to pass into breast milk and harm your baby.
What are the common side effects of plecanatide?
The registry lists Diarrhea among the most-reported FAERS reaction terms for plecanatide. The compiled record contains 1,831 FDA adverse-event reports. These counts are not an individual symptom assessment.
What drug class is plecanatide?
plecanatide belongs to the Guanylate Cyclase-C Agonist drug class. It requires a prescription (Rx). Trulance treats chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).
What pregnancy or breastfeeding source fields are listed for plecanatide?
The FDA label for plecanatide contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.

Other drugs grouped near plecanatide - same-class peers and common alternatives.

Compare plecanatide vs alosetron side-by-side →

Compare beyond drug class

Nationwide peers by FAERS volume & death-report share

Two PlainMeds-derived comparison paths for plecanatide: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.

Medication Guides

Save on plecanatide

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for plecanatide

The FDA label for plecanatide (sold under brand names such as Trulance) classifies it as a prescription-only medication in the Guanylate Cyclase-C Agonist class. Trulance treats chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Official labeling lists 1 commonly reported side effect, including Diarrhea.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,831 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: April 4, 2024

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page